AzTrials
AzTrials

Lumbar Spinal Stenosis (LSS)NCT07303348

Multicenter Clinical Randomized Controlled Trial of Unilateral Biportal Endoscopic Spinal Surgery for Degenerative Grade 1 Spondylolisthesis Complicated With Lumbar Spinal Stenosis

A study testing UBE and PLIF in people with Lumbar Spinal Stenosis (LSS) and Degenerative Spondylolisthesis G1, run by Changhai Hospital at 1 site in China.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

The research objective of this project is to clarify and compare the efficacy of the unilateral biportal endoscopy (UBE) technique and traditional open decompression, fusion and internal fixation surgery in the treatment of patients with Grade Ⅰ degenerative spondylolisthesis complicated with central spinal canal… Read more about this study

Who is it for?
Any age
What is being tested?
UBE and PLIF
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
200 participants
Where
1 siteChina
Study dates
1 Jul 2025to 1 Aug 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Inclusion Criteria Imaging findings: Single-segment Grade Ⅰ lumbar spondylolisthesis complicated with central spinal canal stenosis on imaging examinations; Clinical manifestations: Accompanied by intermittent claudication, radiating pain and numbness of the lower extremities, and other relevant neurological symptoms; Treatment history: No relief of symptoms after more than 3 months of conservative treatment; Informed consent: The patient and their family members are fully informed of the trial details, have signed the informed consent form, and agree to participate in the trial.

Exclusion Criteria Severe spondylolisthesis: Lumbar spondylolisthesis of Grade Ⅱ or higher; Non-degenerative or unstable conditions: Non-degenerative lumbar spine diseases, or significant confirmed lumbar instability; Special pathological or surgical history: Complicated with lumbar spine infection, tumor, trauma, or deformity; or with a history of previous lumbar spine surgery; Systemic comorbidities: Complicated with other systemic diseases that may significantly affect surgical efficacy (such as rheumatoid arthritis, severe osteoporosis, and severe mental illness).

Trial locations and contacts

1 site in 1 country.

China1 site
  • Changhai Hospital

    Shanghai, 200433

Other trials in China

About this study

The research objective of this project is to clarify and compare the efficacy of the unilateral biportal endoscopy (UBE) technique and traditional open decompression, fusion and internal fixation surgery in the treatment of patients with Grade Ⅰ degenerative spondylolisthesis complicated with central spinal canal stenosis through high-quality, prospective, multicenter randomized controlled trials (RCTs), so as to provide high-level clinical research evidence for the expansion of UBE technique indications and its technical promotion.

Read the detailed description

The selection of treatment methods for degenerative Grade Ⅰ spondylolisthesis complicated with lumbar spinal stenosis remains one of the controversial issues in the field of spinal surgery. Degenerative lumbar spondylolisthesis is a spinal sequence disorder caused by factors such as intervertebral disc degeneration and facet joint degeneration, with degeneration recognized as the primary driver of its onset and progression[1]. According to the Meyerding Classification, the severity of lumbar spondylolisthesis can be graded from Ⅰ to Ⅴ[2]. For spondylolisthesis of Grade Ⅱ or above accompanied by neurological symptoms, fusion and internal fixation surgery is generally indicated. In contrast, the surgical management of Grade Ⅰ spondylolisthesis with central spinal canal stenosis involves numerous clinically available approaches, including traditional open fusion surgery, minimally invasive techniques such as MIS-TLIF (Minimally Invasive Transforaminal Lumbar Interbody Fusion), OLIF (Oblique Lumbar Interbody Fusion), and spinal endoscopic surgery, all of which remain subject to ongoing debate[3]. Neither the 2011 Clinical Practice Guidelines for Degenerative Lumbar Spinal Stenosis issued by the North American Spine Society[4], the 2014 Chinese Expert Consensus on the Surgical Treatment Standards for Lumbar Spinal Stenosis[5], nor the 2023 Chinese Expert Consensus on the Diagnosis and Treatment of Degenerative Lumbar Spinal Stenosis[6] provides clear recommendations for the surgical treatment of Grade Ⅰ spondylolisthesis complicated with central spinal canal stenosis.

Unilateral Biportal Endoscopy (UBE)[7] is one of the most rapidly evolving technologies in spinal surgery in recent years, hailed as a minimally invasive spinal endoscopic technique "born for spinal stenosis". It can be applied to treat various lumbar degenerative diseases, including lumbar disc herniation and lumbar spinal stenosis. UBE employs two separate portals (one for endoscopic visualization and one for surgical manipulation) to perform minimally invasive procedures in coordination. As UBE is not restricted by instrument size, it is currently the most efficient among all minimally invasive spinal technologies. UBE for lumbar spinal stenosis integrates the advantages of both open and minimally invasive surgeries: ① Minimal surgical trauma, requiring only two small incisions of 0.8 cm each, with negligible damage to paraspinal muscles; ② Aqueous medium-based surgical field, allowing for effective and precise hemostasis using radiofrequency under endoscopic guidance, which significantly reduces blood loss; ③ Magnified endoscopic visualization enables clear and adequate exposure of the dura mater and nerves, avoiding injury to critical anatomical structures[8]; ④ Under the aforementioned conditions, traditional surgical instruments and specialized tools such as endoscopic drills can be used to achieve bilateral resection of the lamina and ligamentum flavum, as well as spinal canal enlargement, realizing meticulous decompression of the central canal and lateral recess[9]; ⑤ Patients can ambulate on the second day after surgery, with significantly reduced hospital stay, recovery time, postoperative pain, surgical infection rate, and intraoperative blood loss compared with other surgical modalities.

Currently, there is a paucity of international comparative studies between UBE and traditional lumbar spine surgeries. Some scholars have demonstrated through single-center, retrospective studies that compared with transforaminal endoscopic techniques, patients achieve significant improvements in postoperative VAS (Visual Analog Scale) and ODI (Oswestry Disability Index) scores, with the UBE group showing superior VAS and ODI scores within 6 months postoperatively, suggesting the therapeutic advantages of UBE[10]. Additionally, Tan et al. found that compared with traditional open surgery, patients with lumbar spinal stenosis who underwent UBE had shorter operation time, less intraoperative blood loss, shorter hospital stay, milder paraspinal muscle atrophy at 1 year postoperatively, and comparable clinical efficacy (assessed by SF-36, RNS, and RMDQ)[11], highlighting the advantages of UBE over traditional open lumbar spine surgery.

The applicant of this project has previously performed hundreds of UBE procedures. Based on the applicant's clinical experience and the summarized experiences of domestic and international scholars, UBE offers numerous benefits in the treatment of lumbar spinal stenosis. However, there remains significant controversy regarding the suitability of UBE for treating lumbar spinal stenosis complicated with degenerative Grade Ⅰ spondylolisthesis. The traditional viewpoint holds that due to the presence of spinal instability in Grade Ⅰ degenerative spondylolisthesis, simple decompression alone (without fusion) may fail to address the spondylolisthesis, necessitating decompression, reduction, fusion, and fixation to prevent progression of slippage, recurrence of neurological symptoms, and suboptimal clinical outcomes. From the perspective of minimally invasive surgery, the primary pathological issue in lumbar spinal stenosis with Grade Ⅰ degenerative spondylolisthesis is neurological compression caused by spinal stenosis; thus, relieving neurological compression via minimally invasive decompression alone can resolve patients' symptoms. This approach avoids complications associated with decompression plus internal fixation, such as nonunion, infection, and internal fixation failure. Furthermore, UBE causes minimal dissection of paraspinal muscles and negligible damage to facet joints, resulting in minimal impact on spinal stability and a low incidence of postoperative slippage progression or the need for reoperation with internal fixation. Nevertheless, there are currently no long-term clinical follow-up reports on UBE for lumbar spinal stenosis with Grade Ⅰ degenerative spondylolisthesis at home or abroad, and high-quality clinical evidence is particularly lacking.

The significance of this study lies in conducting a multicenter, prospective randomized controlled trial to comprehensively evaluate and compare the clinical efficacy, surgical complications, and postoperative quality of life between UBE and traditional open surgery for Grade Ⅰ degenerative spondylolisthesis complicated with lumbar spinal stenosis from multiple dimensions. This study aims to provide high-level clinical evidence for expanding the indications of UBE in minimally invasive spinal surgery and is expected to update or modify existing guidelines or expert consensus on the diagnosis and treatment of lumbar spinal stenosis.

Main Research Objectives To clarify the efficacy of the Unilateral Biportal Endoscopy (UBE) technique in the treatment of Grade Ⅰ degenerative spondylolisthesis complicated with central spinal canal stenosis; To compare the clinical outcomes between the UBE technique and traditional open decompression, fusion and internal fixation surgery; To provide high-level clinical research evidence for the expansion of UBE technique indications and its technical promotion.

Being tested
UBE, PLIF
Keywords
Grade Ⅰ degenerative spondylolisthesis, lumbar spinal stenosis
Medical subject headings
Spinal Stenosis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • UBEProcedure or surgery

    Unilateral Biportal Endoscopy (UBE) for the treatment of lumbar spinal stenosis combines the advantages of both open surgery and minimally invasive surgery: ① Minimal surgical trauma: Only two small incisions of 0.8 cm are required, resulting in minimal damage to the paraspinal muscles; ② Aqueous medium surgical field: Radiofrequency can be used for effective and precise hemostasis under endoscopy, which significantly reduces blood loss; ③ Endoscopic operation: The surgical field is magnified, allowing clear and adequate exposure of the dura mater and nerves to avoid injury to important structural tissues; ④ Precise decompression: Under the above conditions, traditional surgical instruments and specialized tools such as endoscopic drills can be used to complete bilateral resection of the lamina and ligamentum flavum as well as spinal canal enlargement, achieving meticulous decompression of the central canal and lateral recess.

  • PLIFProcedure or surgery

    Posterior Lumbar Interbody Fusion (PLIF) adopts a midline posterior lumbar approach. On the basis of completing decompression of the spinal canal and nerve root canal, it resects the intervertebral disc tissue of the pathological segment and implants bone grafts (or interbody fusion cages) to achieve intervertebral bony fusion. Meanwhile, it is combined with a pedicle screw internal fixation system to maintain spinal alignment and stability, ultimately aiming to relieve neurological symptoms and restore the mechanical function of the spine.

Study groups in NCT07303348
Study groupRoleWhat they receive
Perform surgery using the Unilateral Biportal Endoscopy (UBE) techniqueExperimentalinclusion Criteria Single-segment Grade Ⅰ lumbar spondylolisthesis complicated with central spinal canal stenosis on imaging examinations; Accompanied by intermittent claudication, radiating pain and numbness of the lower extremities, and other relevant neurological symptoms; No relief of symptoms after more than 3 months of conservative treatment; The patient and their family members are fully informed of the trial details, have signed the informed consent form, and agree to participate in the trial. Exclusion Criteria Lumbar spondylolisthesis of Grade Ⅱ or higher; Non-degenerative lumbar spine diseases, or significant confirmed lumbar instability; Complicated with lumbar spine infection, tumor, trauma, or deformity; or with a history of previous lumbar spine surgery; Complicated with other systemic diseases that may significantly affect surgical efficacy (such as rheumatoid arthritis, severe osteoporosis, and severe mental illness).
Receives: Procedure: UBE
PLIF/TLIFActive comparatorinclusion Criteria Single-segment Grade Ⅰ lumbar spondylolisthesis complicated with central spinal canal stenosis on imaging examinations; Accompanied by intermittent claudication, radiating pain and numbness of the lower extremities, and other relevant neurological symptoms; No relief of symptoms after more than 3 months of conservative treatment; The patient and their family members are fully informed of the trial details, have signed the informed consent form, and agree to participate in the trial. Exclusion Criteria Lumbar spondylolisthesis of Grade Ⅱ or higher; Non-degenerative lumbar spine diseases, or significant confirmed lumbar instability; Complicated with lumbar spine infection, tumor, trauma, or deformity; or with a history of previous lumbar spine surgery; Complicated with other systemic diseases that may significantly affect surgical efficacy (such as rheumatoid arthritis, severe osteoporosis, and severe mental illness).
Receives: Procedure: PLIF

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. VAS

    Status of Visual Analog Scale (VAS) Scores in Two Groups of Patients at 24 Months Postoperatively

    Measured: 24 months after surgery

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Dec 2025
  2. Study start1 Jul 2025
  3. Primary completion30 Dec 2026 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07303348
Sponsor's protocol ID
SPINE-UBE
Status last verified
Dec 2025
First submitted
11 Dec 2025
Last updated
24 Dec 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing UBE and PLIF in people with Lumbar Spinal Stenosis (LSS) and Degenerative Spondylolisthesis G1, run by Changhai Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 24 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

VAS (time frame: 24 months after surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in